Preliminary results of the first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) demonstrate early signs of safety, tolerability and robust immune responses Meeting Abstract
| Authors: | Al Malki, M. M.; Perales, M. A.; Modi, M. D.; Vasu, S.; Nelson, M.; Bui, D.; Kim, S.; Wang, R. P.; Lu, E.; Oelke, M.; Myint, H.; Varela, J. C. |
| Abstract Title: | Preliminary results of the first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) demonstrate early signs of safety, tolerability and robust immune responses |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547203186 |
| DOI: | 10.1182/blood-2020-139342 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 31 -- Source: Wos |
